Objectives: This study evaluated the in vitro pharmacodynamics of combinations of ceftazidime and the nonb-lactam b-lactamase inhibitor, avibactam, against ceftazidime-, piperacillin/tazobactam-and meropenemmultiresistant Pseudomonas aeruginosa by a quantitative time-kill method.
Introduction b-Lactam antibiotics are among the most commonly used antibiotics to treat infections by Pseudomonas aeruginosa. Prolonged use of these agents is associated with the emergence of multipleb-lactam-resistant mutants that express high levels of b-lactamases of the AmpC, extended-spectrum and OXA types, which often result in therapeutic failure.
1,2 A b-lactamase inhibitor is coadministered along with these b-lactams as a way to restore the efficacy of antimicrobials in resistant bacterial infections. However, bacterial strains that express Klebsiella pneumoniae carbapenemases (KPC) or AmpC-type b-lactamases are resistant to these combination chemotherapies. [3] [4] [5] These b-lactamases present a challenge to antimicrobial treatment.
Ceftazidime/avibactam is a new b-lactam/b-lactamase inhibitor combination that was recently approved by the US FDA and the EMA. 6, 7 Avibactam restores ceftazidime potency through inhibition of b-lactamases, which occurs by the formation of a highly stable covalent bond with the enzyme's catalytic serine residue. 8, 9 Several studies have shown increases in in vitro ceftazidime activity in combination with avibactam against clinically isolated P. aeruginosa. [10] [11] [12] [13] Against AmpC expressing P. aeruginosa strains, ceftazidime/avibactam MIC values were 8 mg/L (measured in the presence of avibactam at the susceptibility-testing concentration of 4 mg/L), which is the CLSI interpretive criterion of susceptible for ceftazidime against P. aeruginosa 14, 15 and the interpretation of susceptible for ceftazidime/avibactam. 6, 7 In both lung and thigh infection models in neutropenic mice, the threshold concentration (C T ) of avibactam associated with activity against MDR P. aeruginosa was 1 mg/L. 16 In the lung infection model, the mean time of free avibactam above the threshold concentration (f T . C T ) 1 mg/L associated with stasis was 20%, and for the 2-log kill it was 30%. 16 V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
In the thigh model 40% for stasis and 50% for 1-log kill were obtained. A target of 40%-50% fT . C T 1 mg/L was used for estimating avibactam target attainment against P. aeruginosa. 17, 18 This study investigated the 24 h time-kill pharmacodynamics (PD) of combinations of ceftazidime and avibactam against three ceftazidime-resistant clinical isolates of P. aeruginosa in vitro, while taking account of compound degradation.
Materials and methods

Antimicrobial agents
Avibactam was supplied by Cerexa, Inc. (Oakland, CA, USA). Ceftazidime (potency 770 mg/g; batch no. G263770) was provided by GlaxoSmithKline (King of Prussia, PA, USA) and packaged by IHMA, Inc. (Prospect, IL, USA). Ceftazidime and avibactam stock solutions were prepared fresh prior to experiment by adding drugs to double-distilled water to achieve a concentration of 6.4 and 1.6 mg/mL, respectively. The concentrations of the stock solutions for both ceftazidime and avibactam were determined using a LC-MS/MS method. 19 
Bacteria
Eight clinical isolates of ceftazidime-, piperacillin/tazobactam-and meropenem-resistant P. aeruginosa were obtained from JMI Laboratories (North Liberty, IA, USA). After three subcultures, the inoculation of bacteria was prepared in sterile saline solution, then added to the Mueller-Hinton broth (MHB). The turbidity of the bacterial suspension was adjusted to a McFarland standard value of 0.5 by adding bacteria to a clear bottle containing sterile 0.9% NaCl in double-distilled water. A 10 lL sample of this bacterial suspension was added to 1 mL of MHB to a final bacterial number density of $10 6.5 cfu/mL for the determination of MIC values at different avibactam concentrations. For the time-kill kinetic study, 100 lL of the bacterial suspension was added to 20 mL of MHB to a final number density of $10 6 cfu/mL.
MICs of ceftazidime and ceftazidime/avibactam were measured against samples of two P. aeruginosa isolates (9750 and 10783) that were cultured from the time-kill flasks at 24 h. At the end of the time-kill incubation, suspensions of these two strains were plated on sheep-blood agar and the plates incubated at 37 C for 3 days. Colonies picked at days 1 and 3 posttime-kill were tested for susceptibility to ceftazidime and ceftazidime/avibactam by the method described above for the determination of MIC values at different avibactam concentrations. This was to enable assessment of the stability of any MIC changes that might have occurred under the selection pressure of the time-kill conditions.
Susceptibility testing
MICs of ceftazidime against the eight clinical isolates of P. aeruginosa (244, 465, 1493, 2154, 5241, 9750, 10783, 12432) were determined in combination with 0, 2, 4, 8 and 16 mg/L avibactam by a modified broth macrodilution method. Briefly, the bacterial suspension was added to MHB containing ceftazidime or ceftazidime and avibactam in 24-well plates. The added solutions of ceftazidime and avibactam did not exceed 5% of the final volume, and the final inoculum density was $10 6.5 cfu/mL. The plates containing the bacteria and drug solutions were then incubated at 37 C for 16-20 h. The MIC was determined as the lowest concentration of the antibiotic with no visible bacterial growth. Positive controls containing the bacteria but no drug, and negative controls containing only MHB were also prepared and monitored. This procedure was done in triplicate and modal MIC is reported here.
Constant concentration time-kill kinetics
Constant concentration (i.e. static) time-kill kinetics for ceftazidime/avibactam were determined in vitro against three isolates of P. aeruginosa, numbers 2154, 9750 and 10783. For the purpose of comparing efficacy of the current in vitro constant concentration infection model with the in vivo animal and in vitro hollow-fibre infection models, cross-referencing of specific isolates to previously published studies is provided here. Isolate 2154 was number 3607 studied under simulated human drug exposures in a hollowfibre system and in the thighs of neutropenic mice. 20 Number 10783 was identical to 1388 studied in previous simulated human drug-exposure work 20, 21 and also strain 7 in the ceftazidime/avibactam pharmacokinetic (PK)/PD study in neutropenic mice. 16 Vented Falcon tissue culture flasks (25 cm 
PD analysis
The mean + standard error (SE) bacterial population dynamics displayed as log 10 -transformed bacterial densities (cfu/mL) over 24 h in response to the ceftazidime and avibactam combinations were plotted. The bacterial responses to ceftazidime alone and ceftazidime/avibactam combinations were examined using the log change method, which is used to calculate the change in log 10 cfu/mL from 0 h (cfu 0 ) to time t (10, 24 h; cfu t ), such that logD ¼ log 10 cfu t ð ÞÀlog 10 ðcfu 0 Þ. 22 In both singleantibiotic and avibactam-combination regimens, a reduction of !1 log 10 cfu/mL below the initial inoculum at time t was considered active, and a decrease of !2 log 10 cfu/mL was considered to represent bacterial killing by the combination.
22,23
Drug stability analysis
The natural log-transformed concentrations of ceftazidime and avibactam during the 24 h time-kill kinetic experiments were analysed by a general linear model, using R 3.0.0. In the model, a first-order drug degradation was assumed, because the other participant in the reaction, b-lactamase, is not inactivated in the reaction (and is likely also being continuously produced by any remaining viable bacteria). The response variable was natural logtransformed drug concentration and the predictor variable was time: ln concentration j À Á ¼ btime j þ e j , where time j was the time at which the observation was collected. The natural log-transformed concentrations were assumed to have independent normal distributions with mean l and variance r 2 . Values below the limit of quantification were treated as missing in the regression analysis and 0 in the calculations of means and SE used for graphing the data.
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The half-life of degradation was computed as the negative value of the natural log of 2 divided by the slope of the log-transformed values versus time. The degradation was considered negligible if the half-life was .24 h. This criterion was selected on the basis that elimination half-lives of ceftazidime and avibactam in humans are much shorter, being $1.5 h. 24, 25 In addition, a half-life of 24 h was longer than the duration of the time-kill and MIC experiments; i.e. if the half-life of degradation was .24 h, it could be assumed that the bacterial killing and growth kinetics depended on the initial concentrations of ceftazidime and avibactam rather than on their subsequent decreasing concentrations. Half-lives of degradation ,24 h were observed in some of the flasks, and were associated with bacterial regrowth (see the Results section).
Results
In vitro susceptibility
Ceftazidime MICs in combination with avibactam at 0-16 mg/L against eight ceftazidime-and meropenem-resistant clinical isolates of P. aeruginosa are shown in Table 1 . Dose-response relationships were observed for all eight isolates. At 4 mg/L avibactam, ceftazidime MIC was reduced by $8-16-fold. There was no direct antibacterial activity of avibactam against the three P. aeruginosa isolates (2154, 9750 and 10783) selected for time-kill experiments (data not shown).
Post-time-kill in vitro susceptibility
The post-time-kill ceftazidime MICs against the two more resistant P. aeruginosa isolates that were evaluated in time-kill studies, namely 9750 and 10783, are shown in Table 2 . In comparison to the MIC values in Table 1 , a 2-4-fold increase in MIC was observed at day 1 post-time-kill. The increases were transient, as demonstrated by the general decrease in day 3 post-time-kill MIC values to being identical or within 2-fold of the pre-time-kill MIC values in Table 1 .
Time-kill kinetic studies and drug stability In the absence of avibactam, growth of isolate 2154 was only suppressed for 24 h at high ceftazidime concentrations of at least 256 mg/L (Figure 1, top panels) . At ceftazidime concentrations 128 mg/L an initial kill was followed by bacterial growth, which we have termed 'regrowth'. With 1-16 mg/L avibactam, a concentration-dependent decrease was observed in the ceftazidime concentrations that yielded bacterial killing and inhibition of regrowth. The ceftazidime stability profiles from the same timekill kinetic experiments are shown in the lower rows of Figure 1 (note that these graphs show the percentage of ceftazidime remaining on an arithmetic scale, but the calculations of mean values and half-lives used log 10 concentrations). There was significant ceftazidime degradation at 32 and 64 mg/L in the absence of avibactam, with half-lives considerably shorter than 24 h (Table 3 ). The ceftazidime degradation was associated with higher bacterial number densities, because at the concentrations where drug degradation was rapid, bacterial regrowth was also observed. The half-life of ceftazidime degradation increased with increasing initial ceftazidime concentration, corresponding to greater prevention of bacterial regrowth at the higher concentrations.
Similar patterns to those observed with isolate 2154 were also found with both P. aeruginosa 10783 and 9750 (Figures 2 and 3) . Without avibactam, ceftazidime concentrations that were insufficient to decrease the bacterial number density from the initial inoculum size were associated with substantial ceftazidime degradation and bacterial regrowth. Avibactam reduced the ceftazidime degradation in a dose-dependent manner.
In the absence of avibactam, substantial ceftazidime degradation was elicited by P. aeruginosa isolates 2154 and 10783 when the initial ceftazidime concentration was 64 mg/L (Figures 1 and 2) . The degradation corresponded with full growth over the 24 h period of the assay (upper panels of Figures 1 and 2) . At higher concentrations of ceftazidime, inhibition of early growth slowed the production of biomass, and presumably b-lactamase because degradation did Isolate number based on JMI Lab numbering system. Ceftazidime and avibactam in vitro PK/PD JAC not occur, or was slight. As expected, avibactam prevented the ceftazidime degradation (e.g. lower panels of Figures 1 and 2 at ceftazidime 32 and 64 mg/L). At the lowest ceftazidime concentrations of 0.25-fold the MIC measured in the presence of the respective avibactam concentration (2, 4 and 8 mg/L), a statistically significant and relevant ceftazidime degradation was still observed (Table 3) . However, the corresponding half-life was markedly longer than the 4 h half-lives that were observed in the absence of avibactam.
In the case of P. aeruginosa 9750, in the absence of avibactam, low bacterial killing at all ceftazidime concentrations except 512 mg/L were associated with significant and relevant degradation with half-lives ranging from 4 to 14 h. Even in the presence of avibactam, ceftazidime at concentrations 0.5-fold the corresponding MIC underwent significant degradation with half-lives ,24 h.
There was a significant decrease in the concentration of ceftazidime required to achieve bacterial killing in the presence of avibactam, in agreement with Keepers et al. 26 The bacterial regrowth appeared to result primarily from insufficient initial antimicrobial activity that allowed the bacteria to produce sufficient b-lactamase to catalyse substantial ceftazidime hydrolysis. Avibactam degradation on the other hand was not significant. Table 4 shows the change in log 10 cfu/mL from the initial inoculum at 10 and 24 h of the time-kill study. Ceftazidime/avibactam at MIC resulted in at least a 1 log 10 decrease in the number of cfu/mL at 10 h for all P. aeruginosa isolates evaluated in the time-kill studies, except for 4 mg/L ceftazidime ! 4 mg/L avibactam against P. aeruginosa 2154 where an increase of 1.3 log 10 occurred. Against isolate 2154, ceftazidime/avibactam combinations were cidal (characterized by a .2 log 10 reduction in number of cfu/mL) at 2-8-fold MIC at 24 h, whereas ceftazidime alone required at least !4-fold MIC to achieve bacterial killing. The activities of ceftazidime/avibactam against isolate 10783 resulted in at least 1 log 10 reduction at 1-2-fold MIC at the 10 h timepoint. Owing to bacterial regrowth by 24 h, at least 2-fold MIC was required to yield at least 1 log 10 reduction at the 24 h timepoint.
Against the least susceptible isolate 9750 at 10 h, at least 1 log 10 reduction was observed at 1-fold MIC, and a smaller amount of killing occurred at 0.5-fold MIC for some of the combinations. At 24 h, a reduction in cfu/mL of !1 log 10 mostly occurred only at 4-fold MIC of ceftazidime measured at the corresponding avibactam concentration.
Discussion
This study evaluated the hypothesis that avibactam would enhance the potency of ceftazidime by inhibition of b-lactamase Sy et al. Ceftazidime and avibactam in vitro PK/PD JAC activities in 24 h time-kill studies with ceftazidime-(and meropenem-) resistant P. aeruginosa. The MIC of ceftazidime against all eight P. aeruginosa isolates tested decreased by 8-16-fold with the addition of 4 mg/L avibactam. Bacterial regrowth that occurred by the 24 h timepoint was accompanied by ceftazidime degradation, which was slowed when avibactam was present in the medium. Avibactam provided protection of ceftazidime from degradation, thereby incrementally decreasing the MIC of ceftazidime with increasing avibactam concentration against the P. aeruginosa isolates tested. The in vitro susceptibility-testing concentration of avibactam is fixed at 4 mg/L. 10, 11, [27] [28] [29] This concentration of 4 mg/L avibactam is high enough to inhibit avibactam-susceptible b-lactamases in a challenge panel of bacteria in vitro but without the direct antibacterial activity that can be observed at 8 mg/L against some isolates of Enterobacteriaceae. 28 This approach to optimizing the in vitro susceptibility-testing concentration against a panel of defined challenge strains has been used previously for other b-lactam/b-lactamase inhibitor combinations. 30 In b-lactamase-producing Enterobacteriaceae and P. aeruginosa, an initial bactericidal activity with a 3 log 10 reduction in cfu/mL followed by bacterial regrowth at 24 h was observed in vitro at 128 mg/L ceftazidime in the presence of 4 mg/L avibactam. 26 The regrowth phenomenon has also been observed by others in in vitro time-kill studies with piperacillin/tazobactam; 31,32 a b-lactam plus an aminoglycoside against P. aeruginosa; 33 colistin against Enterobacteriaceae and P. aeruginosa; [34] [35] [36] [37] and meropenem against bla KPC -positive K. pneumoniae. 38 Studies with piperacillin/tazobactam showed that a high inoculum density of 10 6.5 -10 7 cfu/mL resulted in regrowth at 24 h while no regrowth was observed with a lower initial inoculum size of 10 5.3 cfu/mL, 31, 37 indicating that an inoculum effect is associated with regrowth of b-lactamase-producing bacteria.
The starting inoculum for the current study was $10 6.5 cfu/mL, an inoculum size that could potentially account for the regrowth. The study also indicated that high bacterial load in this singlecompartment system was associated with rapid ceftazidime degradation in the test medium at lower initial concentrations of drug (i.e. 1-fold MIC). We suggest that when ceftazidime was depleted in the suspensions under test, the resulting decrease in cidal activity allowed the remaining bacteria to replicate, noting that regrowth did not occur at ceftazidime concentrations !2-fold MIC and was delayed by increasing the concentration of avibactam. The regrowth reported here and by Keepers et al. 26 might be a consequence of analysing the time-kill in a closed system without replenishment of ceftazidime or removal of bacteria. In an infection under therapy ceftazidime is re-administered according to a dosing cycle, so it remains to be determined how best to predict clinical effects from these in vitro time-kill results. Interestingly, a regrowth phenomenon was reported when ceftazidime-resistant P. aeruginosa were exposed to simulated human exposures of ceftazidime and avibactam in a dynamic hollow-fibre infection model. 20 The bacteria that grew in this model were resistant to ceftazidime/avibactam. In contrast, the same ceftazidime and avibactam exposures in neutropenic mice infected in the thigh 20 or lung 21 resulted in bacterial killing without any isolation of such post-exposure resistant variants. 20, 21 As suggested by Crandon et al., 20 there appears to be a hierarchy of severity among models used to evaluate the PD effects of antibacterial agents, namely: in vitro . infections in neutropenic animals . infections in immunocompetent animals.
Berkhout et al. 16 reported that the reduction in ceftazidime MIC on the addition of avibactam was greater in Escherichia coli and Klebsiella pneumoniae than in P. aeruginosa. The 90th percentile MIC of ceftazidime against a collection of 18 ceftazidime-resistant P. aeruginosa isolates decreased from 128 for ceftazidime alone to 16 mg/L, when combined with 4 mg/L avibactam: an 8-fold reduction. The equivalent reduction against 18 E. coli and 29 K. pneumoniae isolates were 64-and !256-fold. 16 The fold reduction in ceftazidime MIC achieved by 4 mg/L avibactam against P. aeruginosa in the present study was also similar to the 8-fold reduction in MIC 50 and MIC 90 reported by Keepers et al. In these incubations the ceftazidime concentrations remained unchanged but regression yielded a net slight increase in assay signal that was interpreted as experimental variation. c Dash indicates that this combination was not tested.
26
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In analysing the attainment of PK/PD exposure targets, based on the mouse neutropenic thigh and lung infection studies, a threshold free drug concentration of avibactam of 1 mg/L has been taken as the point at which, on the declining PK concentration-time curve, inhibition of avibactam-susceptible b-lactamases in ceftazidime-resistant, ceftazidime/avibactamsusceptible, P. aeruginosa is lost; i.e. avibactam concentrations ,1 mg/L during the rising and falling PK cycles of a dosing regimen have been assumed to be pharmacologically inactive, and concentrations higher than that, pharmacologically active. 17, 18 This approach of assessing time-above-threshold somewhat like a switch (analogous to the way that fT . MIC of a b-lactam is approximated as an all-or-none phenomenon in probability of target attainment analyses) [39] [40] [41] enabled probability of PK/PD target attainments to be calculated for populations of simulated patients. 17, 18 The in vitro data reported here and elsewhere 42 show that the potency of ceftazidime-dependent growth inhibition and bacterial killing is increased by increasing the concentration of avibactam. However, that increased potency at higher concentrations early in the PK cycle and the slow reduction in potency lower than the threshold of MIC of ceftazidime and 1 mg/L avibactam are absorbed into the model of using a single % fT . C T as the PK/PD readout. Clearly there remains scope for explicit description of the PD effects of higher and lower concentrations of both avibactam and ceftazidime. Such an explicit description is the aim of the current work, and an accompanying paper describes the mathematic model (S. K. B. Sy, L. Zhuang, H. Xia, M.-E. Beaudoin, V. J. Schuck, W. W. Nichols and H. Derendorf, unpublished results) derived from the experimental data summarized here. The concentration dependence of the PD activity of ceftazidime against P. aeruginosa has been captured previously in analytic mathematical models. [43] [44] [45] Similarly, the concept of 'time above instantaneous MIC' for a b-lactam/b-lactamase inhibitor combination involved mathematical analysis of the PD activities of imipenem and MK-7655 as continuous functions of concentration. 46 The challenge remains how best to use these continuous concentration-dependent models to derive generalizable PK/PD targets for assessing doses in simulated patients potentially infected by any individual member of a population of microorganisms.
In conclusion, avibactam provided protection of ceftazidime from chemical degradation by (the b-lactamases of) three ceftazidime-and meropenem-resistant P. aeruginosa, thereby reducing MICs of ceftazidime in a dose-dependent fashion. It is noted that analysing the relationship between these results and the clinical efficacy of ceftazidime/avibactam against P. aeruginosa infections awaits the analysis of data from clinical trials where P. aeruginosa can be a relatively common causative organism, such as Blank indicates that no time-kill experiment was run for the combination. Italic, bold-italic and bold fonts represent at least -1, -2 and -3 log 10 reduction in the number of cfu/mL from the initial inoculum density, respectively.
Ceftazidime and avibactam in vitro PK/PD JAC nosocomial pneumonia in ventilated and unventilated patients (ClinicalTrials.gov NCT01808092). 47 
